Identification of Burkholderia spp. in the clinical microbiology laboratory: comparison of conventional and molecular methods by Pelt, C. (Cindy) van et al.
JOURNAL OF CLINICAL MICROBIOLOGY,
0095-1137/99/$04.0010
July 1999, p. 2158–2164 Vol. 37, No. 7
Copyright © 1999, American Society for Microbiology. All Rights Reserved.
Identification of Burkholderia spp. in the Clinical Microbiology
Laboratory: Comparison of Conventional and
Molecular Methods
CINDY VAN PELT,1* CEES M. VERDUIN,1 WIL H. F. GOESSENS,1 MARGREET C. VOS,1
BURKHARD TU¨MMLER,2 CHRISTINE SEGONDS,3 FRANS REUBSAET,4
HENRI VERBRUGH,1 AND ALEX VAN BELKUM1
Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center Rotterdam EMCR,
3015 GD Rotterdam,1 and National Institute of Public Health and the Environment RIVM, 3720 BA Bilthoven,4
The Netherlands; Klinische Forschergruppe Molekulare Pathologie der Mukoviszidose, Zentrum Biochemie
und Zentrum Kinderheilkunde, Medizinische Hochschule Hannover, D-30623 Hannover,
Germany2; and Observatoire Cepacia, Laboratoire de Bacteriologie-Virologie-Hygiene,
Hoˆpital Rangueil, 31403 Toulouse Ce´dex 4, France3
Received 30 November 1998/Returned for modification 4 February 1999/Accepted 26 March 1999
Cystic fibrosis (CF) predisposes patients to bacterial colonization and infection of the lower airways. Several
species belonging to the genus Burkholderia are potential CF-related pathogens, but microbiological identifi-
cation may be complicated. This situation is not in the least due to the poorly defined taxonomic status of these
bacteria, and further validation of the available diagnostic assays is required. A total of 114 geographically
diverse bacterial isolates, previously identified in reference laboratories as Burkholderia cepacia (n 5 51),
B. gladioli (n 5 14), Ralstonia pickettii (n 5 6), B. multivorans (n 5 2), Stenotrophomonas maltophilia (n 5 3), and
Pseudomonas aeruginosa (n 5 11), were collected from environmental, clinical, and reference sources. In
addition, 27 clinical isolates putatively identified as Burkholderia spp. were recovered from the sputum of Dutch
CF patients. All isolates were used to evaluate the accuracy of two selective growth media, four systems for
biochemical identification (API 20NE, Vitek GNI, Vitek NFC, and MicroScan), and three different PCR-based
assays. The PCR assays amplify different parts of the ribosomal DNA operon, either alone or in combination
with cleavage by various restriction enzymes (PCR-restriction fragment length polymorphism [RFLP] anal-
ysis). The best system for the biochemical identification of B. cepacia appeared to be the API 20NE test. None
of the biochemical assays successfully grouped the B. gladioli strains. The PCR-RFLP method appeared to be
the optimal method for accurate nucleic acid-mediated identification of the different Burkholderia spp. With
this method, B. gladioli was also reliably classified in a separate group. For the laboratory diagnosis of
B. cepacia, we recommend parallel cultures on blood agar medium and selective agar plates. Further identi-
fication of colonies with a Burkholderia phenotype should be performed with the API 20NE test. For final
confirmation of species identities, PCR amplification of the small-subunit rRNA gene followed by RFLP
analysis with various enzymes is recommended.
Pulmonary colonization with Burkholderia cepacia is associ-
ated with a poor clinical prognosis for patients with cystic
fibrosis (CF) (23). A relatively constant fraction of CF patients
in Western European countries appear to be colonized with
this usually multiple-antibiotic-resistant organism. However,
the prevalence in individual CF centers may differ widely due
to epidemic bursts of infection and problems with the identi-
fication of the microorganism. Interestingly, in some CF pa-
tients, long-term colonization can occur without an adverse
effect on lung function (8). On the other hand, some individ-
uals deteriorate rapidly after colonization, and death may oc-
cur within 1 to 6 months (8). There is also evidence that
particular clonal isolates of B. cepacia can be easily transmitted
from person to person (12, 25, 31, 32). Separating B. cepacia-
colonized or -infected patients from other CF patients has
been used to prevent bacterial spread, but this practice has a
severe social and psychological impact on the patients and
their family members (10). In The Netherlands, colonization
with B. cepacia is considered a contraindication for lung trans-
plantation. However, this point of view is not internationally
acknowledged (19). Because of the serious implications of the
identification of B. cepacia in patients with CF, microbiological
diagnosis should be carried out as accurately as possible. How-
ever, the isolation and reliable identification of B. cepacia have
been complicated and difficult (6, 9, 15, 21). Although the
pathogenicity of the closely related species B. gladioli has not
been definitely assessed, reliable pathogenicity studies can only
be performed once precise species identification can be
achieved in the routine microbiology laboratory.
B. cepacia has recently been described as a complex of mul-
tiple genetic types, or genomovars: B. cepacia (genomovar I),
B. multivorans (genomovar II), genomovars III and IV (36),
and the closely related new species B. vietnamiensis (formerly
genomovar IV) (4, 9, 33). Strains of all of these genomovars, B.
vietnamiensis, and B. gladioli have been isolated from CF pa-
tients. Several of the Burkholderia spp. are of commercial im-
portance because they can be used as biopesticides, as plant
growth promoters, or for the degradation of environmental
pollutants (4, 18, 22, 33).
In The Netherlands, the identification of putative B. cepacia
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isolates is generally performed by conventional biochemical
analyses. Different institutions use different approaches; even
when essentially the same diagnostic scheme has been applied,
several discrepancies have become apparent upon close eval-
uation and comparison of the diagnostic data obtained. More-
over, the lack of a well-evaluated and generally accepted diag-
nostic “gold standard” technique is considered a significant
limitation by all of those involved in the management of and
care for CF patients. In this communication, we address the
lack of gold standard microbiology techniques and describe the
results of conventional and molecular identification proce-
dures applied to a large and diverse collection of Burkholderia
strains. Finally, a method for the optimal identification of
B. cepacia and other clinically relevant Burkholderia spp. is
suggested on the basis of the results of this comparative study.
MATERIALS AND METHODS
Collection and initial identification of strains. Several strains of B. cepacia,
B. gladioli, Ralstonia pickettii (formerly B. pickettii [39]), B. multivorans, Stenotro-
phomonas maltophilia, and Pseudomonas aeruginosa were obtained from expert
microbiology centers in Germany, Canada, France, Sweden, and The Nether-
lands. The characteristics of the strains are given in Table 1. Note that some of
the reference strains obtained from the different participants are the same.
B. cepacia ATCC 25416, for instance, was obtained from three centers. The strain
used in our Rotterdam laboratory was obtained directly from the American Type
Culture Collection and, as such, provided an accurate species control specimen.
TABLE 1. Geographical, clinical, and microbiological characteristics of the strain collectiona
Origin Organism No. ofisolates Source
Method of identification by the study
participants
RIVMb B. cepacia 2 Sputa, lung biopsy 16S rRNA sequence
B. gladioli 5 CF patient Biochemical
S. maltophilia 3 Sputa
University of British Columbia,
Vancouver, British
Columbia, Canada
B. cepacia 4 CF patient API 20NE, biochemical (15, 23)
1 Soil (ATCC 25416)
B. multivorans 1 CF patient
1 Soil (ATTC 17616)
B. gladioli 2 CF patient, CGD
1 Onion (ATCC 10248)
Sweden B. cepacia 4 CCUG 788, CCUG 12691,
CCUG 9631, CCUG 36978
R. pickettii 2 CCUG 3314, CCUG 3318
B. gladioli 2 CCUG 1782, CCUG 2115
Medizinische Hochschule,
Hannover, Germany
B. cepacia 33 CF patient SpeI fragment pattern and/or
sequencing of 16S rRNA, BCSA,
OFPBL, API 20NE
1 Environment
B. gladioli 2 CF patient
Universite Paul Sabatier,
Toulouse, France
B. cepacia 3 ATCC 25416, ATCC 17759,
ATCC 25609
B. gladioli 2 ATCC 10248, ATCC 19302
AZR; SKZc B. cepacia 2 ATCC 25416, ATCC 17759
1 SKMM
P. aeruginosaf 11 ATCC MicroScan and PC480-PC1250 PCR
CF patient
R. pickettii 4 CF patient MicroScan and API 20NE, BCSA
Environment
Unspecified 19 CF patient PC480-PC1250 PCR
LVFd Unspecified 2 Patient
2 CF patient Biochemical
AZUe Unspecified 4 CF patient API 20NE
a For B. cepacia, 10 reference strains, 2 environmental isolates, and 37 clinical strains were included in the present analysis. For B. gladioli, these figures are 4, 1, and
4, respectively. One clinical isolate and one environmental isolate of B. multivorans are included. For P. aeruginosa, 11 reference and clinical strains were studied. Two
R. pickettii reference strains and four clinical isolates of this species were analyzed. Finally, 25 “unidentified” bacterial isolates were included. The SpeI fragment patterns
were generated by pulsed-field gel electrophoresis of DNA macrorestriction fragments. SKMM, Foundation for Quality Control in Medical Microbiology, Groningen,
The Netherlands; ATCC, American Type Culture Collection, Manassas, Va.; CCUG, Culture Collection of the University of Goteborg, Goteborg, Sweden; CGD,
chronic granulomatous disease.
b National Institute of Public Health and the Environment RIVM, Bilthoven, The Netherlands.
c AZR, Erasmus University Medical Center Rotterdam EMCR, Rotterdam, The Netherlands; SKZ, Sophia Children’s Hospital, Rotterdam, The Netherlands.
d Laboratory for Public Health Friesland, Leeuwarden, The Netherlands.
e University Hospital Utrecht, Utrecht, The Netherlands.
f P. aeruginosa strains were not isolated from CF patients and did not have a mucoid phenotype.
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Table 1 summarizes the methods of identification used in the strain contributor
home laboratories.
All strains were characterized by a combination of microbiological, biochem-
ical, and molecular methods at a single, central laboratory (Department of
Medical Microbiology and Infectious Diseases, Erasmus University Medical
Centre Rotterdam EMCR, Rotterdam, The Netherlands). All individual assays
were performed batchwise by a single researcher to prevent experimental day-
to-day and person-to-person variability.
Presumptive identification with selective culture media. All strains were sub-
cultured on B. cepacia selective agar (BCSA) (15) and oxidation-fermentation
base-polymyxin B-bacitracin-lactose medium (OFPBL; Becton-Dickinson, Hei-
delberg, Germany) (38). The plates were incubated for 5 days at 30 or 37°C.
Growth on BCSA is considered indicative of B. cepacia. Colonies on OFPBL
were suspected of being B. cepacia if they were yellow as a result of lactose
oxidation in the presence of the bromothymol blue indicator. The natural yellow
pigment of bacterial strains other than B. cepacia may lead to misidentification
and a false-positive result, however.
Biochemical testing. All bacterial isolates were characterized on the basis of
phenotypic characteristics by use of four commercial assays. Prior to inoculation
into these systems, a subculture was made on a brucella blood agar plate (bio-
Merieux, Marcy l’Etoile, France), which was incubated at 37°C for 18 h. Oxidase
production was determined by means of a dipstick oxidase test (Difco, Detroit,
Mich.).
API 20NE. For all strains, a cell suspension having a 0.5 McFarland optical
density (MF) standard was made with 0.85% NaCl. Appropriate amounts of this
material were added to the wells of an API 20NE strip (bioMerieux), some of
which were covered with mineral oil. The strips were incubated for 48 h at 30°C,
and the results were recorded by visual inspection and scored with an APILAB
PLUS software package as proposed by the manufacturer.
Vitek analysis. For identification, two different Vitek cards (from bioMerieux
at location given above and at s’-Hertogenbosch, The Netherlands) were used.
One card is routinely used for the identification of gram-negative bacteria (GNI),
and the other card has been developed for the industrial identification of non-
fermenters (NFC). The latter is not commercially available yet. For all strains, a
suspension having a 1.0 MF standard was made with 0.45% NaCl. The cards,
filled with the suspensions, were placed in a specific tray, which was placed in the
Vitek combined reader-incubator. Identification with the NFC was performed by
use of the equipment of the Dutch bioMerieux representative in s’-Hertogen-
bosch, The Netherlands.
MicroScan analysis. For identification by use of MicroScan technology (Dade
International, West Sacramento, Calif.), the so-called “negative urine combo
type 1” was used. This test format also assays the susceptibility of strains to
antibiotics frequently used against urinary tract infections and/or infections
caused by gram-negative bacteria. A cell suspension having a 0.5 MF standard
was made with 0.45% NaCl. One hundred microliters of this suspension was
pipetted into a tube with water containing pluronic acid to avoid air bubbling.
The MicroScan kit was filled with the cell suspension and placed in a WalkAway
reader-incubator for overnight processing.
PCR analyses. PCR-mediated identification was performed by means of three
methods directed to various parts of the ribosomal gene operon (26, 29, 35, 37).
Prior to DNA isolation, strains were grown overnight at 37°C on brucella blood
agar plates. One to three colonies were suspended in 25 mM Tris-HCl (pH
8.0)–10 mM EDTA–50 mM glucose and treated with proteinase K and 10%
sodium dodecyl sulfate (SDS). DNA was purified by affinity chromatography
with guanidine hydrothiocyanate and Celite (Janssen Pharmaceuticals, Beerse,
Belgium) (5). The DNA concentration was estimated by electrophoresis with 1%
agarose gels (Hispanagar; Sphaero Q, Leiden, The Netherlands) in the presence
of known quantities of lambda DNA as references. The PCR mixtures used for
all amplifications contained 10 mM Tris-HCl (pH 9.0), 50 mM KCl, 2.5 mM
MgCl2, 0.01% gelatin, 0.1% Triton X-100, 0.2 mM respective deoxyribonucleo-
tide triphosphate, 2 U of Taq polymerase (Sphaero Q), and 50 pmol of each
primer. Amplification of DNA was performed with a model 60 thermocycler
(Biomed, Theres, Germany). Amplicons were analyzed by electrophoresis with
1% agarose gels in the presence of a 100-bp DNA ladder for size assessment
(Gibco/BRL Life Technologies, Breda, The Netherlands).
Two diagnostic PCR assays were performed; the first was done with primers
PC1 and PC2 (35). This assay amplifies the ribosomal internal transcribed spacer
(ITS) spanning the distance between the 16S and the 23S ribosomal genes.
Approximately 300 ng of DNA was added to a PCR mixture. Amplification
involved an initial denaturation of 2 min at 94°C, followed by 30 cycles of 30 s at
94°C, 30 s at 68°C, and 1 min at 72°C. A final extension of 30 min at 72°C was
performed. The target sequence comprised 323 bp. In the second diagnostic PCR
assay, primers PC480 and PC1250 were used (26). This amplification reaction,
targeting the 16S ribosomal gene, should result in the specific detection of
B. cepacia. Approximately 150 ng of DNA was added to a standard PCR mixture.
Amplification was performed according to the following scheme: initial denatur-
ation of 5 min at 96°C, followed by 25 cycles of 15 s at 96°C, 30 s at 52°C, and 1.5
min at 70°C. A final extension of 5 min at 70°C was included. The target sequence
was 770 bp long.
PCR-RFLP. Amplification of the 16S rRNA gene, followed by restriction
enzyme-mediated fragmentation of the amplicon (restriction fragment length
polymorphism [RFLP] analysis), should result in Burkholderia sp.-specific band-
ing patterns (29, 37). Approximately 50 ng of DNA was added to a PCR mixture
as described above. PCR was performed with primers rD1 and fD1 and a 35-cycle
program of 2 min at 95°C, 30 s at 42°C, and 4 min at 72°C, with a final extension
of 20 min at 72°C. The amplicons, approximately 1,500 bp long, were analyzed
and quantified on a 1% agarose gel (Hispanagar). After amplification, the sam-
ples were treated with four different restriction enzymes (AluI, CfoI, MspI, and
DdeI; Boehringer GmbH, Mannheim, Germany). These restriction enzymes
were selected on the basis of homology searches performed for Burkholderia
sp.-specific 16S rRNA sequences available through GenBank (see Fig. 2). One
microliter of enzyme mixture containing 1 U of restriction enzyme and the
appropriate buffer components was added to 9 ml of the amplified product. The
mixture was incubated for 2 h at 37°C. The sizes of the restriction fragments were
documented by electrophoresis, ethidium bromide staining, UV transillumina-
tion, and photography.
RESULTS
Culture-based assays. All of the B. cepacia and B. gladioli
strains were positive in the oxidase assay. The results of growth
analyses with selective agar plates are shown in Table 2. Forty-
eight of 50 strains of B. cepacia grew on both BCSA and
OFPBL plates. The two isolates not growing on BCSA plates
were gentamicin-sensitive B. cepacia, a result which implies
that gentamicin susceptibility may not be a 100% reliable spe-
cies discriminator. These isolates were derived from a single
German CF patient, showed identical random amplified poly-
morphic DNA patterns, were negative for the B. cepacia epi-
demicity marker, and belonged to the B. cepacia genomovar III
group (16).
Biochemical identification. It must be mentioned explicitly
that the taxons B. gladioli and B. multivorans are not included
in the databases of any of the assays used here. The results of
biochemical assays are shown in Table 3. Overall, the API
20NE and the Vitek GNI were the most accurate. The API
20NE gave a doubtful but essentially correct identification
(“low level of discrimination”) for 6% of the strains; for only
2% of the strains could the system not provide a bacterial
identification at all. The Vitek GNI could not identify 10% of
the tested strains. None of the systems was able to identify
B. gladioli correctly and efficiently. The API 20NE identified
36% of these strains as B. cepacia. The Vitek GNI identified
21% of B. gladioli strains as B. cepacia, whereas the Vitek NFC
and the MicroScan scored 50% and none, respectively, of 14
strains of B. gladioli as B. cepacia. The MicroScan identified
43% of the strains as nonfermenters, and for 57% of the strains
an incorrect identification was given. The two strains from
Canada which were presented as B. multivorans were identified
as B. cepacia by all four systems. All systems could reliably
identify two strains of R. pickettii, the P. aeruginosa strains, and
two strains of S. maltophilia. The Vitek NFC approach did not
correctly identify one of the S. maltophilia strains tested.
PCR assays. The results shown in Table 4 and Figure 1
summarize the experimental data obtained with the PCR-
RFLP procedure. The diagnostic PCRs with primers PC480-
TABLE 2. Growth of Burkholderia spp. and other gram-negative
bacilli on two selective media
Organisma No. ofisolates
No. (%) growing on:
BCSA OFPBL
B. cepacia 50 48 (96) 50 (100)
B. gladioli 14 6 (43) 8 (57)
R. pickettii 2 2 (100) 0 (0)
B. multivorans 2 2 (100) 2 (100)
S. maltophilia 3 0 (0) 1 (33)
P. aeruginosa 11 0 (0) 0 (0)
a Identification as provided by the different strain contributors.
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PC1250 and PC1-PC2 could not accurately differentiate B.
cepacia from B. gladioli (Table 4). The PCR with the PC1-PC2
primer combination, whose major drawback is that it lacks
sensitivity for B. cepacia, provided a positive result for only 22
of 50 B. cepacia strains (sensitivity, 44%). The specificity of this
PCR was good, since no positive results were encountered
among the different B. gladioli strains. Although the PC480-
PC1250 PCR correctly recognized all strains from both species
(100% sensitivity), it did not distinguish between B. cepacia
and B. gladioli. Moreover, other species may produce positive
signals as well (e.g., Alcaligenes spp. [unpublished observa-
tion]), rendering this diagnostic application useless.
RFLP typing of ribosomal amplicons turned out to be the
most appropriate technique for discriminating B. cepacia from
B. gladioli. All B. gladioli strains were found identical when
AluI and DdeI digests were considered (type BC). For B. ce-
pacia, the AluI pattern was characteristic (type A). These as-
says were diagnostically accurate and corroborated the initial
laboratory identification. On the other hand, the RFLP anal-
yses demonstrated intraspecies heterogeneity (types AAAA,
AAAB, and ABBB for B. cepacia, for instance). Interestingly,
several of these single RFLP patterns were shared by the two
species (A and B patterns for MspI, for instance). The RFLP
patterns obtained for the other species clearly differed from
the B. cepacia and B. gladioli patterns (e.g., types DDDE,
EEFH, and CCCD). Clearly, strains identified as B. cepacia
were genetically heterogeneous, as were P. aeruginosa strains
(types EEFH, FEFH, and GFFH). It is interesting to note that
19 of the B. cepacia strains generated a type AAAA PCR-
RFLP pattern, which is identical to that recorded for the
B. multivorans strains. This finding is in agreement with the
recent proposals of Vandamme et al. (36), who separated B.
multivorans from the bulk group of B. cepacia as a separate
type. Type AAAA is also encountered among clinical isolates,
substantiating the fact that isolates belonging to this specific
genomovar have colonizing and/or pathogenic potential.
Analysis of clinical Burkholderia sp. isolates. Twenty of 27
(74%) of the clinical isolates that were suspected of being
TABLE 3. Comparison of four systems of biochemical identification for Burkholderia spp. and various other bacterial speciesa
Organism No. ofisolates System
No. (%) of isolates with the following identification:
Correctb Incomplete Incorrect Unidentified
B. cepacia 50 Vitek GNI 45 (90) 0 (0) 0 (0) 5 (10)
Vitek NFC 34 (68) 0 (0) 11 (22) 5 (10)
API 20NE 45 (90) 3 (6) 1 (2) 1 (2)
MicroScan 34 (68) 0 (0) 16 (32) 0 (0)
B. gladioli 14 Vitek GNI 0 (0) 0 (0) 6 (43) 8 (57)
Vitek NFC 0 (0) 0 (0) 9 (64) 5 (56)
API 20NE 0 (0) 0 (0) 14 (100) 0 (0)
MicroScan 0 (0) 0 (0) 14 (100) 0 (0)
R. pickettii 6 Vitek GNI 6 (100) 0 (0) 0 (0) 0 (0)
Vitek NFC 4 (100) 0 (0) 0 (0) 0 (0)
API 20NE 4 (66) 1 (17) 0 (0) 1 (17)
MicroScan 6 (100) 0 (0) 0 (0) 0 (0)
B. multivorans 2 Vitek GNI 2 (100) 0 (0) 0 (0) 0 (0)
Vitek NFC 2 (100) 0 (0) 0 (0) 0 (0)
API 20NE 2 (100) 0 (0) 0 (0) 0 (0)
MicroScan 2 (100) 0 (0) 0 (0) 0 (0)
S. maltophilia 3 Vitek GNI 3 (100) 0 (0) 0 (0) 0 (0)
Vitek NFC 2 (66) 0 (0) 0 (0) 1 (33)
API 20NE 3 (100) 0 (0) 0 (0) 0 (0)
MicroScan 3 (100) 0 (0) 0 (0) 0 (0)
P. aeruginosa 11 Vitek GNI 11 (100) 0 (0) 0 (0) 0 (0)
Vitek NFC 10 (91) 0 (0) 0 (0) 1 (9)
API 20NE 11 (100) 0 (0) 0 (0) 0 (0)
MicroScan 11 (100) 0 (0) 0 (0) 0 (0)
Unspecified clinical isolatesc
B. cepacia 20 Vitek GNI 9 (45) 5 (25) 1 (5) 5 (25)
Vitek NFC 8 (40) 0 (0) 0 (0) 12 (60)
API 20NE 16 (80) 3 (15) 1 (5) 0 (0)
MicroScan 5 (25) 0 (0) 15 (75) 0 (0)
P. aeruginosa 5 Vitek GNI 1 (20) 2 (40) 2 (40) 0 (0)
Vitek NFC 2 (40) 0 (0) 0 (0) 3 (60)
API 20NE 4 (80) 0 (0) 1 (20) 0 (0)
MicroScan 0 (0) 0 (0) 5 (100) 0 (0)
a Note that B. gladioli is not mentioned in the databases of the systems.
b Identification to the species level with a probability of more than 80%.
c For the evaluation of this group of isolates, PCR-RFLP was considered the gold standard for identification.
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B. cepacia appeared to be genuine B. cepacia when PCR-RFLP
was considered the gold standard for identification. This find-
ing implies that the different Dutch strain contributors possibly
misidentified at least seven strains, five of which were identi-
fied as P. aeruginosa by RFLP. This figure is even higher when
the other forms of identification are considered. Based on
Vitek NFC analysis, for instance, 12 of 20 B. cepacia strains
(60%) would not have been identified correctly. It must be
emphasized here that the Vitek NFC has not yet been qualified
for laboratory-based medical microbiological diagnostic proce-
dures. The API 20NE misidentified only a single strain, under-
scoring its excellent diagnostic potential. Not all strain contrib-
utors misidentified the strains; since most of the strains were
isolated from CF patients and showed aberrant characteristics,
the microbiologists involved wanted to exclude the possibility
of B. cepacia carriage.
DISCUSSION
The genetic defect causing CF predisposes patients to an
aberrant pulmonary susceptibility to infectious disease. Several
of the bacterial species encountering a suitable ecological
niche in the lungs of CF patients are especially pathogenic for
the host. B. cepacia, a microorganism originally identified as
the causative agent of soft rot of onions, is a well-known rep-
resentative of this particular group; in 20% of patients who
become colonized with this species, the rapidly fatal B. cepacia
syndrome may occur (11). Microbiological detection of B. ce-
pacia appears to be complicated, and laboratory proficiency
testing was particularly disappointing in the past (34). Difficul-
ties and inaccuracies at the level of laboratory procedures have
been documented even when simple plating procedures are
used for screening (15). Mix-ups with relatively nonpathogenic
bacterial species have been described (21), and even commer-
cially available diagnostic tests have failed (6). Also, the tax-
onomy of Burkholderia spp. is still evolving, and the pathogenic
potential of the diverse species and subspecies for humans has
not been elucidated yet (10). Major biological and genetic
diversity among isolates of B. cepacia subspecies cultured from
the same environmental source can be demonstrated (7). Vari-
ation in the flagellin genes of B. cepacia can be demonstrated
for subdivisions within the species as well (14). In addition, it
has been demonstrated that clinical isolates of B. cepacia may
have characteristics of B. gladioli (3), a species for which some
records of severe infections exist as well (1, 13, 17, 20, 28, 30).
The issues mentioned here warrant in-depth studies on the
value of the currently available diagnostic tools for the identi-
fication of B. cepacia.
In the present communication, we tried to define the best
procedures for diagnosing the presence of Burkholderia spp. in
the sputum of CF patients. A collection of Burkholderia strains
was obtained from several reference laboratories. Based on
our results, we suggest the use of either BCSA or OFPBL
plates for the initial isolation of B. cepacia directly from clinical
material. The sensitivity of these growth media appeared to be
excellent (96 and 100%, respectively); the specificity, however,
was not 100%. Because of the growth of species other than
B. cepacia on selective agar, such agar cannot be used for the
definitive identification of a strain as B. cepacia but can provide
a useful first screen, as stated previously (15). In the presence
of colonization or infection by B. gladioli, many strains will not
be detected if this procedure is used as the single diagnostic
assay.
It was quite striking to find that the automated assays, such
FIG. 1. PCR-RFLP analysis of Burkholderia spp. and other gram-negative
bacilli. The four panels display the results obtained by restriction of small-subunit
rRNA amplicons with the restriction endonucleases indicated below the panels.
The lanes show the RFLP types found in each enzyme assay. DNA templates
were derived from the following strains (from left to right) (RFLP type):
B. cepacia Dutch patient isolate (AAAA), B. cepacia ATCC 25416 (AAAB),
B. cepacia H134-6 (ABBB), B. gladioli ATCC 10248 (BBBC), B. gladioli RIVM
95-665 (BBEC), R. pickettii CCUG3314 (DDDE), P. aeruginosa ATCC 27853
(EEFH), and S. maltophilia RIVM 96-330 (CCCD). Lane MW, molecular weight
(MW) standard.
TABLE 4. Results of PCR-mediated identification
Organisma No. ofstrains
No. (%) identified
with the following
primer pair:
PCR-RFLP resultsd
PC1-PC2b PC480-PC1250c Type
No. (%)
of strains
with the
indicated
type
B. cepacia 50 22 (44) 50 (100) AAAB 20 (40)
AAAA 19 (38)
ABBB 11 (22)
B. gladioli 14 0 14 (100) BBBC 10 (71)
BBEC 4 (29)
R. pickettii 6 0 0 DDDE 2 (100)
B. multivorans 2 0 2 (100) AAAA 2 (100)
S. maltophilia 3 0 0 CCCD 3 (100)
P. aeruginosa 11 0 0 EEFH 3 (27)
FEFH 6 (55)
GFFH 2 (18)
Clinical isolatee 27 2 (7) 21 (78) AAAA 18 (67)
AAAB 2 (7)
EEFH 5 (19)
Other 2 (7)
a Identification as provided by the strain contributors.
b Increased level of discordance for B. cepacia compared to results with
PC1250-PC480, but correctly negative for the other species.
c Apparently suited for identifying both Burkholderia species; however, non-
Burkholderia species also may be identified.
d Order of restriction enzymes used: AluI, CfoI, MspI, and DdeI.
e RFLP was considered the gold standard for identification.
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as Vitek and MicroScan, performed with varying but consis-
tently insufficient accuracy. Only the Vitek GNI reliably iden-
tified most of the B. cepacia strains, but it encountered major
problems with B. gladioli strains. Improvement in both cards
and software is certainly needed for all automated systems
currently available. The major outcome of the present analysis
is the fact that molecular identification by PCR-RFLP analysis
is superior to the biochemical and microbiological species
identification procedures used here, although it should be em-
phasized that the API 20NE performed satisfactorily, as doc-
umented previously (15, 27). No international gold standard
for the routine laboratory identification of clinically relevant
Burkholderia species exists to date, so the definition of accurate
sensitivities and specificities for the tests used in the present
communication remains a topic for future investigations. The
PCR-RFLP procedure was found to be in excellent agreement
with strain identification provided by the different study par-
ticipants.
Genetic mosaicism has been proposed on the basis of phe-
notypic studies for B. cepacia and B. gladioli (3). On the basis
of the currently known small-subunit rRNA gene sequences
(Fig. 2) and the PCR-RFLP test, intraspecific polymorphism
can be anticipated and noted, respectively. Depending on the
restriction enzyme, species-specific RFLP patterns or RFLP
patterns that are shared between the two species can be ob-
served. Whether this observation relates to genetic exchange
or mere coincidence, based on lack of variability in the ribo-
somal region that is targeted by the enzyme, requires addi-
tional DNA sequencing studies. In the present study, no clearly
overlapping characteristics were noted among the diverse types
of the strains and the tests that were performed. Only for a
B. cepacia strain with type ABBB was the PCR with primer
pair PC1-PC2 positive, although exceptions may be encoun-
tered in the future. It would be interesting to determine
whether the RFLPs coincide with the epidemicity and patho-
genicity of the strain (24, 25).
For adequate characterization of the strains of Burkholderia
spp. described in this report, we suggest that the PCR-RFLP
procedure be used as the most definitive means of identifica-
tion. However, it must be emphasized that PCR-based meth-
ods are not generally available to the clinical microbiologist.
We recommend that microbiologists initiate characterization
with a diagnostic agar followed by API 20NE. Routine micro-
biology procedures should be used prior to the tests mentioned
above in order to exclude all nonrelevant bacterial species.
The PCR-RFLP procedure seems to be a reliable tool for
discriminating strains of B. cepacia versus B. gladioli. This
technique should facilitate more detailed studies on the clinical
relevance of the latter species in CF and other diseases.
Whereas previously a comparison of the endotoxicity of lipo-
polysaccharide isolated from both species was a measure of
clinical relevance (10), now precise species identification can
replace superficial lipopolysaccharide characteristics for a
more species-defining feature. In order to make another im-
portant step forward, the DNA assays used here and those
newly described in the literature (2) should be adapted for
PCR directly from sputum samples.
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